Hmm I thought John docherty was more the science guy. The money they raised is great. It’s up to them now. Some of these studies get very expensive so yea the money could last a few years or under a year depending what direction they go. It’s all about getting the licensing deals and reoccurring revenue. So I guess I worded my last point wrong. It’s not how long the money lasts it’s being efficient and using it to get to those deals. Hopefully we get good news with BAT. Sucks we gave away so much of nicotine division to Altria.
You painted this picture in all rose colors. Feels like Lexaria trades near all time high, not all time low. Like nobody is losing money right now. Good job.
News 
Market Data 
Discover 
AI
